QUOTE AND NEWS
StreetInsider.com  Feb 28  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Guidance/AtriCure%2C+Inc.+%28ATRC%29+Misses+Q4+Loss+Views+by+2cShare%3B+Guides+FY13+Revs/8145006.html for the full story.
StreetInsider.com  Jan 16  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Equity+Offerings/AtriCure+%28ATRC%29+Prices+Offering/8011752.html for the full story.
Benzinga  Jan 15  Comment 
AtriCure (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced that it intends to...
StreetInsider.com  Jan 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Guidance/AtriCure+%28ATRC%29+Pre-announces+Q4+Revenue+In-Line/7989031.html for the full story.
Benzinga  Nov 16  Comment 
Piper Jaffray raised its rating on AtriCure (NASDAQ: ATRC) from Neutral to Overweight and increased its price target from $6 to $10. Piper Jaffray said, "We are upgrading ATRC shares to Overweight from Neutral (and raising our PT to $10 from...
Benzinga  Nov 16  Comment 
Benzinga  Nov 1  Comment 
AtriCure (NASDAQ: ATRC), a medical device company and a leader in cardiac surgical ablation systems for the treatment of atrial fibrillation, or AF, and systems for the exclusion of the left atrial appendage, today announced that Michael Carrel...
Benzinga  Aug 3  Comment 
JMP Securities downgraded AtriCure (NASDAQ: ATRC) from “outperform” to “market perform.” AtriCure's shares closed at $8.10 yesterday. AtriCure's PEG ratio is -1.40. Analysts at UBS downgraded Allstate (NYSE: ALL) from “buy” to...
Benzinga  Jul 3  Comment 
Piper Jaffray reiterates its Overweight rating on AtriCure (NASDAQ: ATRC) and reduces its price target from $14 to $12. Piper Jaffray notes, "We are lowering our PT for ATRC from $14/share to $12/share to reflect the decreasing demand for our...
Benzinga  Feb 28  Comment 
Barrington Reserach reiterated its AtriCure (NASDAQ: ATRC) Outperform rating in a research report published today. Barrington Research has a $17 price target on AtriCure. In the report, Barrington Research stated, "We are reiterating our...
Benzinga  Feb 28  Comment 
According to Piper Jaffray, AtriCure (NASDAQ: ATRC) price target is raised to $14. Piper Jaffray said that AtriCure has been shackled by its lack of ability to market the company's key atrial fibrillation (AF) products for that indication....




 
TOP CONTRIBUTORS

AtriCure, Inc. is a medical device company focused on developing, manufacturing, and selling innovative surgical devices to create precise lesions, or scars, in soft tissues. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure bipolar ablation system as a standard treatment alternative during open-heart surgical procedures to safely, rapidly, and reliably create lesions in cardiac, or heart, tissue to block the abnormal electrical impulses that cause atrial fibrillation (AF), a rapid, irregular quivering of the upper chambers of the heart. Some leading cardiothoracic surgeons have also begun using the system as a sole-therapy minimally invasive treatment for AF. The general commercial release of this system in the U.S. was in January 2003. AtriCure's business and future growth depend on the continued use of the bipolar ablation system in the treatment of AF, which is considered an off-label use of the system because the indications for which the system has received the U.S. Food & Drug Administration (FDA) clearance or approval is the ablation and coagulation of soft tissues during certain non-cardiac-related surgical procedures and the ablation of cardiac tissue. AtriCure consummated an initial public offering of its common stock on August 10, 2005.

In addition to the bipolar ablation system, AtriCure products include the Isolator pen, the Wolf dissector, and an ablation device that uses cryothermy, or extreme cold, to ablate tissues. The AtriCure bipolar ablation system consists of the ablation and sensing unit (ASU) and a series of uniquely designed disposable Isolator handpieces. The ASU is a compact power generator that uses AtriCure's proprietary software and delivers bipolar radio-frequency energy. The pen-shaped ablation device has been cleared by the FDA for the surgical ablation of cardiac tissue and for temporary pacing, sensing, stimulating, and recording during the evaluation of cardiac arrhythmias. The product is well suited to be used in connection with AtriCure's system to create transmural lesions in difficult-to-reach cardiac tissue. The Wolf dissector is cleared by the FDA for use on thoracic and certain other non-cardiac soft tissues. This dissection tool is used by surgeons to separate tissues surrounding the heart to provide access to key anatomical structures that are targeted for ablation during sole-therapy minimally invasive AF treatments. A dissection tool for the open procedure was released in early 2007. In 2006, domestic open heart, domestic minimally invasive sole-therapy (MIS), and international contributed 60%, 29%, and 11%, respectively to total revenue. The isolator bipolar pen has been divided between the minimally invasive and open-heart products.




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki